Treatment After Progression on CDK 4/6i in mBC
Not really appropriate title, but there are useful info in it.
Nguyen https://www.onclive.com/view/treatme...sion-on-cdk4-6 |
Re: Treatment After Progression on CDK 4/6i in mBC
Therapy After Cyclin-Dependent Kinase Inhibition in Metastatic
Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Novel Treatment Strategies https://acsjournals.onlinelibrary.wi...02/cncr.32931c Endocrine therapy has been the standard of care for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer since the 1970s, improving survival while avoiding the toxicities associated with cytotoxic chemotherapy. However, all HR-positive tumors ultimately develop resistance to endocrine therapy. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have more recently become an important component of the management of this breast cancer subtype, significantly delaying time to the disease progres- sion and improving survival when combined with endocrine therapy. However, as with endocrine therapy alone, treatment resistance remains a universal phenomenon. As more women receive CDK4/6 inhibitors as part of their treatment, the management of de novo and acquired resistance to combined CDK4/CDK6 inhibitor plus endocrine therapy regimens has emerged as an important clinical chal- lenge. Several resistance mechanisms have been described, including alterations in the CDK4/6/cyclin D complex or its major effector retinoblastoma protein(pRb), bypass signaling through other cyclin/CDK complexes and activation of upstream signaling pathways, in particular the PI3K/mTOR pathway, but robust biomarkers to predict resistance remain elusive, and the role for continuing CDK4/6 inhibitors after progression remains under investigation. Novel strategies being evaluated in clinical trials include the continuation of CDK4/6 inhibitors through progression, as well as triplet therapy combinations with PI3K inhibitors or immune checkpoint inhibitors. Cancer 2020;0:1-17. © 2020 American Cancer Society. |
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?
https://ascopost.com/issues/april-25...tment-is-best/ |
All times are GMT -7. The time now is 05:54 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021